Macrolide-resistant mycobacterium avium complex lung disease: Analysis of 102 consecutive cases

Annals of the American Thoracic Society

Volumn 13, Issue 11, 2016, Pages 1904-1911

  Morimoto, Kozo ^a   Namkoong, Ho ^b   Hasegawa, Naoki ^b   Nakagawa, Taku ^c   Morino, Eriko ^d   Shiraishi, Yuji ^a   Ogawa, Kenji ^c   Izumi, Kiyohiko ^e,f   Takasaki, Jin ^d   Yoshiyama, Takashi ^a   Hoshino, Yoshihiko ^g   Matsuda, Shuichi ^a   Hayashi, Yuta ^c   Sasaki, Yuka ^a   Ishii, Makoto ^b   Kurashima, Atsuyuki ^a   Nishimura, Tomoyasu ^b   Betsuyaku, Tomoko ^b   Goto, Hajime ^a  

^a Japan Anti Tuberculosis Association   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c National Hospital Organization Higashi Nagoya National Hospital   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

^f NAGASAKI UNIVERSITY   (Japan)

^g NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Clarithromycin; Multidrug resistant tuberculosis; Prognosis; Side effect

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CLARITHROMYCIN; ETHAMBUTOL; KANAMYCIN; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; DIZZINESS; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING DISORDER; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM AVIUM COMPLEX; OBSERVATIONAL STUDY; PROGNOSIS; RASH; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; VISUAL DISORDER; ATYPICAL MYCOBACTERIOSIS; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECTS; INAPPROPRIATE PRESCRIBING; JAPAN; KAPLAN MEIER METHOD; LUNG DISEASE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; ETHAMBUTOL; FEMALE; HUMANS; INAPPROPRIATE PRESCRIBING; JAPAN; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LUNG DISEASES; MACROLIDES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84995538969     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201604-246OC     Document Type: Article

References (36)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175: 367-416.
2. Published erratum appears in Am J Respir Crit Care Med 175:744-5.
3. Philley JV, Griffith DE. Treatment of slowly growing mycobacteria. Clin Chest Med 2015;36:79-90.
4. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996;153: 1766-1772.
5. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K, Caccitolo J, Alvarez J, Shepherd S, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;174: 928-934.
6. Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc 2014;11:9-16.
7. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurek GH. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994;149: 1335-1341.
8. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996;23:983-989.
9. months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000;30:288-292.
10. Morimoto K. Macrolide resistant Mycobacterium avium complex pulmonary disease - clinical analysis of 95 cases: an NTM-TRC (Tokyo Research Consortium) study [abstract]. Am J Respir Crit Care Med 2015;191:A5256.
11. Inagaki T, Yagi T, Ichikawa K, Nakagawa T, Moriyama M, Uchiya K, Nikai T, Ogawa K. Evaluation of a rapid detection method of clarithromycin resistance genes in Mycobacterium avium complex isolates. J Antimicrob Chemother 2011;66:722-729.
12. van Ingen J, Kuijper EJ. Drug susceptibility testing of nontuberculous mycobacteria. Future Microbiol 2014;9:1095-1110.
13. CLSI. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes, 2nd ed. CLSI document M24 A-2. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
14. Yoshiyama T, Morimoto K, Okumura M, Sasaki Y, Ogata H, Shiraishi Y, Kudou S. Long term outcome of multidrug-resistant TB patients in Fukujuji Hospital in Japan. Trans R Soc Trop Med Hyg 2014;108: 589-590.
15. Plotinsky RN, Talbot EA, von Reyn CF. Proposed definitions for epidemiologic and clinical studies of Mycobacterium avium complex pulmonary disease. PLoS One 2013;8:e77385.
16. Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis 2013;19:1889-1891.
17. Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K, Ogata H, Kurashima A, Gemma A, Kudoh S. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc 2014;11:1-8.
18. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015; 36:13-34.
19. Ichiki H, Watanabe A, Ueda S, Sato C, Abe M. [A study of adverse drug reactions in the treatment of pulmonary Mycobacterium avium complex disease [in Japanese]. Kekkaku 2012;87:487-490.
20. Bermudez LE, Nash KA, Petrofsky M, Young LS, Inderlied CB. Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model. J Infect Dis 1996;174:1218-1222.
21. May T, Brel F, Beuscart C, Vincent V, Perronne C, Doco-Lecompte T, Saint-Marc T, Dautzenberg B, Grosset J. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clin Infect Dis 1997;25:621-629.
22. Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest 2014;146:276-282.
23. Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2015;191:96-103.
24. Miwa S, Shirai M, Toyoshima M, Shirai T, Yasuda K, Yokomura K, Yamada T, Masuda M, Inui N, Chida K, et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc 2014; 11:23-29.
25. Bermudez LE, Nash K, Petrofsky M, Young LS, Inderlied CB. Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice. Antimicrob Agents Chemother 2000;44:2619-2622.
26. Aksamit TR, Philley JV, Griffith DE. Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials. Respir Med 2014;108: 417-425.
27. Sano C, Tatano Y, Shimizu T, Yamabe S, Sato K, Tomioka H. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents 2011;37:296-301.
28. Koh WJ, Hong G, Kim SY, Jeong BH, Park HY, Jeon K, Kwon OJ, Lee SH, Kim CK, Shin SJ. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother 2013;57:2281-2285.
29. Horne DJ, Spitters C, Narita M. Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Int J Tuberc Lung Dis 2011; 15:1485-1489, i. (i.).
30. Morimoto K, Yoshiyama T, Kuse M, Okumura M, Sasaki Y, Yoshimori K, Ogata H, Kurashima A, Kudoh S. [Clinical experience using rifabutin for treating infection with Mycobacterium tuberculosis in elderly Japanese patients [in Japanese]. Kekkaku 2013;88: 625-628.
31. Shiraishi Y. Surgical treatment of nontuberculous mycobacterial lung disease. Gen Thorac Cardiovasc Surg 2014;62:475-480.
32. Mitchell JD. Surgical approach to pulmonary nontuberculous mycobacterial infections. Clin Chest Med 2015;36:117-122.
33. World Health Organization. Global tuberculosis report 2014. A report from the WHO. Geneva: World Health Organization; 2014.
34. Jamal MA, Maeda S, Nakata N, Kai M, Fukuchi K, Kashiwabara Y. Molecular basis of clarithromycin-resistance in Mycobacterium avium intracellulare complex. Tuber Lung Dis 2000;80:1-4.
35. Christianson S, Grierson W, Wolfe J, Sharma MK. Rapid molecular detection of macrolide resistance in the Mycobacterium avium complex: are we there yet? J Clin Microbiol 2013;51: 2425-2426.
36. Bag R, Griffith DE. Therapy for Mycobacterium avium complex lung disease. It ain't perfect, but it's progress. Am J Respir Crit Care Med 2015;191:14-16.